Jefferies Group reissued their buy rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a research report report published on Thursday morning. They currently have a $91.00 target price on the biopharmaceutical company’s stock.
Several other research firms also recently commented on GILD. Piper Jaffray Cos. reduced their price objective on Gilead Sciences from $114.00 to $108.00 and set an overweight rating for the company in a research note on Tuesday, July 26th. Royal Bank Of Canada reduced their price objective on Gilead Sciences from $120.00 to $105.00 and set an outperform rating for the company in a research note on Tuesday, July 26th. Robert W. Baird reaffirmed an outperform rating and set a $122.00 price objective (down from $135.00) on shares of Gilead Sciences in a research note on Tuesday, July 26th. Credit Suisse Group AG reaffirmed a buy rating and set a $115.00 price objective (down from $120.00) on shares of Gilead Sciences in a research note on Tuesday, July 26th. Finally, Needham & Company LLC cut Gilead Sciences from a buy rating to a hold rating and boosted their target price for the stock from $84.60 to $88.55 in a research report on Tuesday, July 26th. Eleven equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $104.34.
Gilead Sciences (NASDAQ:GILD) opened at 79.25 on Thursday. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11. The company has a market cap of $104.58 billion, a P/E ratio of 6.96 and a beta of 1.06. The stock’s 50 day moving average price is $79.45 and its 200 day moving average price is $85.72.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.15 EPS. Analysts expect that Gilead Sciences will post $11.76 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a $0.47 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.37%. Gilead Sciences’s dividend payout ratio is currently 16.56%.
In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $77.48, for a total value of $7,748,000.00. Following the transaction, the insider now owns 3,287,810 shares of the company’s stock, valued at $254,739,518.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares in the company, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. boosted its position in shares of Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock worth $159,794,000 after buying an additional 258,807 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares in the last quarter. Temasek Holdings Private Ltd boosted its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares in the last quarter. Omega Advisors Inc. acquired a new position in shares of Gilead Sciences during the first quarter worth about $47,491,000. Finally, Riverhead Capital Management LLC boosted its position in shares of Gilead Sciences by 84.2% in the first quarter. Riverhead Capital Management LLC now owns 756,049 shares of the biopharmaceutical company’s stock worth $69,450,000 after buying an additional 345,518 shares in the last quarter. 77.94% of the stock is currently owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.